AU6228000A - The use of retinoid receptor antagonists in the treatment of prostate carcinoma - Google Patents

The use of retinoid receptor antagonists in the treatment of prostate carcinoma

Info

Publication number
AU6228000A
AU6228000A AU62280/00A AU6228000A AU6228000A AU 6228000 A AU6228000 A AU 6228000A AU 62280/00 A AU62280/00 A AU 62280/00A AU 6228000 A AU6228000 A AU 6228000A AU 6228000 A AU6228000 A AU 6228000A
Authority
AU
Australia
Prior art keywords
treatment
receptor antagonists
prostate carcinoma
retinoid receptor
retinoid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU62280/00A
Inventor
Geoffrey Brown
Roshantha A. Chandraratna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Sales LLC
Original Assignee
Allergan Sales LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Sales LLC filed Critical Allergan Sales LLC
Publication of AU6228000A publication Critical patent/AU6228000A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
AU62280/00A 1999-07-23 2000-07-21 The use of retinoid receptor antagonists in the treatment of prostate carcinoma Abandoned AU6228000A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14528799P 1999-07-23 1999-07-23
US60145287 1999-07-23
PCT/US2000/019849 WO2001007028A2 (en) 1999-07-23 2000-07-21 The use of retinoid receptor antagonists in the treatment of prostate carcinoma

Publications (1)

Publication Number Publication Date
AU6228000A true AU6228000A (en) 2001-02-13

Family

ID=22512422

Family Applications (1)

Application Number Title Priority Date Filing Date
AU62280/00A Abandoned AU6228000A (en) 1999-07-23 2000-07-21 The use of retinoid receptor antagonists in the treatment of prostate carcinoma

Country Status (2)

Country Link
AU (1) AU6228000A (en)
WO (1) WO2001007028A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1689700A1 (en) * 2003-11-25 2006-08-16 Novo Nordisk A/S Novel salicylic anilides
SI1937244T1 (en) 2005-09-30 2018-12-31 Io Therapeutics, Llc Treatment of cancer with specific rxr agonists
MX352727B (en) 2011-12-13 2017-12-06 Dartmouth College Autoimmune disorder treatment using rxr agonists.
PL3368080T3 (en) 2015-10-31 2023-09-11 Io Therapeutics, Inc. Treatment of nervous system disorders using combinations of rxr agonists and thyroid hormones
EP4098257A1 (en) 2015-11-25 2022-12-07 IO Therapeutics, Inc. Use of cyp26-resistant rar alpha selective agonists in the treatment of cancer
KR20230164204A (en) 2016-03-10 2023-12-01 아이오 테라퓨틱스, 인크. Treatment of autoimmune diseases with combinations of rxr agonists and thyroid hormones
EP3426303B1 (en) 2016-03-10 2022-06-15 IO Therapeutics, Inc. Treatment of muscular disorders with combinations of rxr agonists and thyroid hormones
CN115671292A (en) 2016-06-10 2023-02-03 Io治疗公司 Receptor selective retinoid and rexinoid compounds and immunomodulators for cancer immunotherapy
SG11202000230VA (en) 2017-07-11 2020-02-27 Vertex Pharma Carboxamides as modulators of sodium channels
IL302133A (en) 2017-07-13 2023-06-01 Io Therapeutics Inc Immunomodulatory retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
AU2018326617B2 (en) 2017-08-31 2022-12-01 Io Therapeutics, Inc. Rar selective agonists in combination with immune modulators for cancer immunotherapy
CA3076373A1 (en) 2017-09-20 2019-03-28 Io Therapeutics, Inc. Treatment of disease with esters of selective rxr agonists
US10966950B2 (en) 2019-06-11 2021-04-06 Io Therapeutics, Inc. Use of an RXR agonist in treating HER2+ cancers
US11896558B2 (en) 2021-12-07 2024-02-13 Io Therapeutics, Inc. Use of an RXR agonist and taxanes in treating Her2+ cancers

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958954A (en) * 1995-09-01 1999-09-28 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US5688957A (en) * 1995-12-29 1997-11-18 Allergan (3"-thioxacyclohex-1"-enyl)!-but-3'-ene-1'-ynyl!aryl and (3"-thioxacyclohex-1"-enyl)!-but-3'-ene-1'-ynyl!heteroaryl carboxylic acids and esters having retinoid-like biological activity
US5763635A (en) * 1996-06-21 1998-06-09 Allergan Tetrahydronaphthalene derivatives substituted in the 8 position with alkyhidene groups having retinoid and/or retinoid antagonist-like biological activity
US5808124A (en) * 1996-06-21 1998-09-15 Allergan O- or S-substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US5773594A (en) * 1996-06-21 1998-06-30 Allergan Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US5739338A (en) * 1996-11-05 1998-04-14 Allergan N-aryl substituted tetrahydroquinolines having retinoid agonist, retinoid antagonist or retinoid inverse agonist type biological activity
US5728846A (en) * 1996-12-12 1998-03-17 Allergan Benzo 1,2-g!-chrom-3-ene and benzo 1,2-g!-thiochrom-3-ene derivatives
US5919970A (en) * 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity

Also Published As

Publication number Publication date
WO2001007028A2 (en) 2001-02-01
WO2001007028A3 (en) 2001-08-30

Similar Documents

Publication Publication Date Title
AU1293101A (en) Ep4 receptor selective agonists in the treatment of osteoporosis
HRP20060251B1 (en) Substituted oxasolidinones and their use
AU2666901A (en) Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
ZA200108413B (en) Use of glycosyceramide synthesis inhibitors in therapy.
AU6228000A (en) The use of retinoid receptor antagonists in the treatment of prostate carcinoma
AU4923200A (en) Isothiazolecarboxamides and their use as microbicides
AU3086900A (en) Device for the complex treatment of disorders of the prostate
AU2962200A (en) Use of agonists or antagonists of mip-3a in therapy
AU2001248971A1 (en) Use of npy y1 receptor agonists in the treatment of pain conditions
IL145775A0 (en) 13 transmembrane protein expressed in prostate cancer
HUP0202339A3 (en) Use of cortisol antagonists in the treatment of heat failure
AU2193797A (en) Delivery of therapeutic agents to the prostate
AU2297201A (en) Uses of antileukoprotease in carcinoma
GB2356362A9 (en) Ultrasonic nebuliser
GB9812662D0 (en) Therapeutic use
GB9929772D0 (en) New use
AU2001285707A1 (en) Peptides of the alpha1-adrenergic receptor and their use for psoriasis
GB9911238D0 (en) Therapeutic use
GB9811624D0 (en) Therapeutic use
GB9923117D0 (en) Insect-paper and methods for its formation and use
AU2021700A (en) Methods of using temozolomide in the treatment of cancers
TW392510U (en) Ultrasonic atomizing device
AU1342301A (en) Improvements in water generating devices
GB9812664D0 (en) Therapeutic use
TW443645U (en) Grounding line set structure for personal use

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase